Sygen Pharmaceuticals Ltd, a leading Nigerian pharmaceutical company, and ORx Pharmaceuticals Corporation, based in Ontario, Canada, have announced the formation of a pioneering joint venture named Sygen-ORx Biosciences Ltd.
This strategic partnership aims to revolutionize healthcare by addressing pharmaceutical drug security challenges through collaborative innovation.
ORx Pharmaceuticals, affiliated with the Toronto Institute of Pharmaceutical Technology, North America’s premier post-graduate institute for pharmaceutical technology and research, is renowned for its commitment to advancing medical science and improving patient care.
The company brings a wealth of expertise in drug development and commercialization, backed by patented technologies and a strong track record of delivering transformative therapies across various therapeutic areas.
Sygen Pharmaceuticals, recognized for its innovative approach and dedication to scientific excellence, complements ORx’s strengths by focusing on developing high-quality medications and enhancing access to advanced healthcare solutions.
The joint venture, Sygen-ORx Biosciences Ltd, represents a powerful alliance of vision, expertise, and a shared commitment to improving patient outcomes. By combining their resources, knowledge, and capabilities, the two companies aim to accelerate the development and commercialization of cutting-edge therapies, addressing unmet medical needs, and improving healthcare access globally.
According to the framework agreement, Sygen-ORx Biosciences Ltd will concentrate on developing improved formulations of generic pharmaceuticals, particularly those with established clinical efficacy that have already received regulatory approval and achieved significant commercial success.
The joint venture will also focus on advancing innovative drug discovery programs, bringing new treatments to the regional and global pharmaceutical markets, and reducing costs while increasing access to high-quality branded generic medicines across Africa.
In addition to establishing the joint venture company, Sygen and ORx will leverage their combined expertise in global drug discovery, research and development, commercialization, and distribution to support the venture. This collaboration is expected to accelerate open innovation, particularly in early-stage drug discovery, and drive significant advancements in healthcare.
According to the Chief Execitive Officer of ORx Pharmaceuticals,, Dr Alexander MacGregor: “Sygen-ORx Biosciences will build upon the foundation of excellence established by ORx and Sygen, ushering in a new era of healthcare innovation”,
He said: “With a shared commitment to scientific excellence and integrity. Sygen-ORX Biosciences is positioned to make a significant impact in the healthcare landscape, shaping the future of medicine for generations to come”.
Also speaking, Sygen Pharmaceutical, Charles Ogunwuyi said: “Collaboration is at the heart of our mission at Sygen Pharmaceuticals, and we are excited to embark on this transformative journey with ORx Pharmaceuticals. “Together, as Sygen ORx, we have the opportunity to amplify our impact and drive innovation in healthcare, ultimately improving the lives of patients in Africa and beyond.”
“Through our partnership with ORx Pharmaceuticals, we can leverage our collective strengths to deliver meaningful solutions that address critical medical challenges and advance patient care.”
